Components of the cell death machine and drug sensitivity of the National Cancer Institute cell line panel

Phyllis A. Svingen, David Loegering, Joe Rodriquez, Xue Wei Meng, Peter W. Mesner, Susan Holbeck, Anne Monks, Stan Krajewski, Dominic A. Scudiero, Edward A. Sausville, John C. Reed, Yuri A. Lazebnik, Scott H Kaufmann

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

Purpose: According to some studies, susceptibility of cells to anticancer drug-induced apoptosis is markedly inhibited by targeted deletion of genes encoding apoptotic protease activating factor 1 (Apaf-1) or certain caspases. Information about levels of these polypeptides in common cancer cell types and any possible correlation with drug sensitivity in the absence of gene deletion is currently fragmentary. Experimental Design: Immunoblotting was used to estimate levels of Apaf-1 as well as procaspase-2, -3, -6, -7, -8, and -9 in the 60-cell-line panel used for drug screening by the National Cancer Institute. Sensitivity of the same lines to >80,000 compounds was determined with 48-hoer sulforhodamine B binding assays. Additional 6-day assays were performed for selected agents. Results: Levels of Apaf-1 and procaspases varied widely. Apaf-1 and procaspase-9, which are implicated in caspase activation after treatment of cells with various anticancer drugs, were detectable in all of the cell lines, with levels of Apaf-1 ranging from ∼1 × 105 to 2 × 106 molecules per cell and procaspase-9 from ∼5 × 103 to ∼1.6 × 105 molecules per cell. Procaspase-8 levels ranged from 1.7 × 105 to 8 × 10 6 molecules per cell. Procaspase-3, a major effector caspase, varied from undetectable to ∼1.6 × 106 molecules per cell. Correlations between levels of these polypeptides and sensitivity to any of a variety of experimental or conventional antineoplastic agents in either 2-day or 6-day cytotoxicity assays were weak at best. Conclusions: With the exception of caspase-3, all of the components of the core cell-death machinery are expressed in all of the cell lines examined. Despite variations in expression, levels of any one component are not a major determinant of drug sensitivity in these cells in vitro.

Original languageEnglish (US)
Pages (from-to)6807-6820
Number of pages14
JournalClinical Cancer Research
Volume10
Issue number20
DOIs
StatePublished - Oct 15 2004

Fingerprint

National Cancer Institute (U.S.)
Apoptotic Protease-Activating Factor 1
Cell Death
Cell Line
Pharmaceutical Preparations
Caspase 3
Caspase 9
Gene Deletion
Caspases
lissamine rhodamine B
Effector Caspases
Caspase 2
Peptides
Preclinical Drug Evaluations
Caspase 8
Immunoblotting
Antineoplastic Agents
Research Design
Apoptosis

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Components of the cell death machine and drug sensitivity of the National Cancer Institute cell line panel. / Svingen, Phyllis A.; Loegering, David; Rodriquez, Joe; Meng, Xue Wei; Mesner, Peter W.; Holbeck, Susan; Monks, Anne; Krajewski, Stan; Scudiero, Dominic A.; Sausville, Edward A.; Reed, John C.; Lazebnik, Yuri A.; Kaufmann, Scott H.

In: Clinical Cancer Research, Vol. 10, No. 20, 15.10.2004, p. 6807-6820.

Research output: Contribution to journalArticle

Svingen, PA, Loegering, D, Rodriquez, J, Meng, XW, Mesner, PW, Holbeck, S, Monks, A, Krajewski, S, Scudiero, DA, Sausville, EA, Reed, JC, Lazebnik, YA & Kaufmann, SH 2004, 'Components of the cell death machine and drug sensitivity of the National Cancer Institute cell line panel', Clinical Cancer Research, vol. 10, no. 20, pp. 6807-6820. https://doi.org/10.1158/1078-0432.CCR-0778-02
Svingen, Phyllis A. ; Loegering, David ; Rodriquez, Joe ; Meng, Xue Wei ; Mesner, Peter W. ; Holbeck, Susan ; Monks, Anne ; Krajewski, Stan ; Scudiero, Dominic A. ; Sausville, Edward A. ; Reed, John C. ; Lazebnik, Yuri A. ; Kaufmann, Scott H. / Components of the cell death machine and drug sensitivity of the National Cancer Institute cell line panel. In: Clinical Cancer Research. 2004 ; Vol. 10, No. 20. pp. 6807-6820.
@article{1d56d4494038471b89b860307b01b0da,
title = "Components of the cell death machine and drug sensitivity of the National Cancer Institute cell line panel",
abstract = "Purpose: According to some studies, susceptibility of cells to anticancer drug-induced apoptosis is markedly inhibited by targeted deletion of genes encoding apoptotic protease activating factor 1 (Apaf-1) or certain caspases. Information about levels of these polypeptides in common cancer cell types and any possible correlation with drug sensitivity in the absence of gene deletion is currently fragmentary. Experimental Design: Immunoblotting was used to estimate levels of Apaf-1 as well as procaspase-2, -3, -6, -7, -8, and -9 in the 60-cell-line panel used for drug screening by the National Cancer Institute. Sensitivity of the same lines to >80,000 compounds was determined with 48-hoer sulforhodamine B binding assays. Additional 6-day assays were performed for selected agents. Results: Levels of Apaf-1 and procaspases varied widely. Apaf-1 and procaspase-9, which are implicated in caspase activation after treatment of cells with various anticancer drugs, were detectable in all of the cell lines, with levels of Apaf-1 ranging from ∼1 × 105 to 2 × 106 molecules per cell and procaspase-9 from ∼5 × 103 to ∼1.6 × 105 molecules per cell. Procaspase-8 levels ranged from 1.7 × 105 to 8 × 10 6 molecules per cell. Procaspase-3, a major effector caspase, varied from undetectable to ∼1.6 × 106 molecules per cell. Correlations between levels of these polypeptides and sensitivity to any of a variety of experimental or conventional antineoplastic agents in either 2-day or 6-day cytotoxicity assays were weak at best. Conclusions: With the exception of caspase-3, all of the components of the core cell-death machinery are expressed in all of the cell lines examined. Despite variations in expression, levels of any one component are not a major determinant of drug sensitivity in these cells in vitro.",
author = "Svingen, {Phyllis A.} and David Loegering and Joe Rodriquez and Meng, {Xue Wei} and Mesner, {Peter W.} and Susan Holbeck and Anne Monks and Stan Krajewski and Scudiero, {Dominic A.} and Sausville, {Edward A.} and Reed, {John C.} and Lazebnik, {Yuri A.} and Kaufmann, {Scott H}",
year = "2004",
month = "10",
day = "15",
doi = "10.1158/1078-0432.CCR-0778-02",
language = "English (US)",
volume = "10",
pages = "6807--6820",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "20",

}

TY - JOUR

T1 - Components of the cell death machine and drug sensitivity of the National Cancer Institute cell line panel

AU - Svingen, Phyllis A.

AU - Loegering, David

AU - Rodriquez, Joe

AU - Meng, Xue Wei

AU - Mesner, Peter W.

AU - Holbeck, Susan

AU - Monks, Anne

AU - Krajewski, Stan

AU - Scudiero, Dominic A.

AU - Sausville, Edward A.

AU - Reed, John C.

AU - Lazebnik, Yuri A.

AU - Kaufmann, Scott H

PY - 2004/10/15

Y1 - 2004/10/15

N2 - Purpose: According to some studies, susceptibility of cells to anticancer drug-induced apoptosis is markedly inhibited by targeted deletion of genes encoding apoptotic protease activating factor 1 (Apaf-1) or certain caspases. Information about levels of these polypeptides in common cancer cell types and any possible correlation with drug sensitivity in the absence of gene deletion is currently fragmentary. Experimental Design: Immunoblotting was used to estimate levels of Apaf-1 as well as procaspase-2, -3, -6, -7, -8, and -9 in the 60-cell-line panel used for drug screening by the National Cancer Institute. Sensitivity of the same lines to >80,000 compounds was determined with 48-hoer sulforhodamine B binding assays. Additional 6-day assays were performed for selected agents. Results: Levels of Apaf-1 and procaspases varied widely. Apaf-1 and procaspase-9, which are implicated in caspase activation after treatment of cells with various anticancer drugs, were detectable in all of the cell lines, with levels of Apaf-1 ranging from ∼1 × 105 to 2 × 106 molecules per cell and procaspase-9 from ∼5 × 103 to ∼1.6 × 105 molecules per cell. Procaspase-8 levels ranged from 1.7 × 105 to 8 × 10 6 molecules per cell. Procaspase-3, a major effector caspase, varied from undetectable to ∼1.6 × 106 molecules per cell. Correlations between levels of these polypeptides and sensitivity to any of a variety of experimental or conventional antineoplastic agents in either 2-day or 6-day cytotoxicity assays were weak at best. Conclusions: With the exception of caspase-3, all of the components of the core cell-death machinery are expressed in all of the cell lines examined. Despite variations in expression, levels of any one component are not a major determinant of drug sensitivity in these cells in vitro.

AB - Purpose: According to some studies, susceptibility of cells to anticancer drug-induced apoptosis is markedly inhibited by targeted deletion of genes encoding apoptotic protease activating factor 1 (Apaf-1) or certain caspases. Information about levels of these polypeptides in common cancer cell types and any possible correlation with drug sensitivity in the absence of gene deletion is currently fragmentary. Experimental Design: Immunoblotting was used to estimate levels of Apaf-1 as well as procaspase-2, -3, -6, -7, -8, and -9 in the 60-cell-line panel used for drug screening by the National Cancer Institute. Sensitivity of the same lines to >80,000 compounds was determined with 48-hoer sulforhodamine B binding assays. Additional 6-day assays were performed for selected agents. Results: Levels of Apaf-1 and procaspases varied widely. Apaf-1 and procaspase-9, which are implicated in caspase activation after treatment of cells with various anticancer drugs, were detectable in all of the cell lines, with levels of Apaf-1 ranging from ∼1 × 105 to 2 × 106 molecules per cell and procaspase-9 from ∼5 × 103 to ∼1.6 × 105 molecules per cell. Procaspase-8 levels ranged from 1.7 × 105 to 8 × 10 6 molecules per cell. Procaspase-3, a major effector caspase, varied from undetectable to ∼1.6 × 106 molecules per cell. Correlations between levels of these polypeptides and sensitivity to any of a variety of experimental or conventional antineoplastic agents in either 2-day or 6-day cytotoxicity assays were weak at best. Conclusions: With the exception of caspase-3, all of the components of the core cell-death machinery are expressed in all of the cell lines examined. Despite variations in expression, levels of any one component are not a major determinant of drug sensitivity in these cells in vitro.

UR - http://www.scopus.com/inward/record.url?scp=6044273762&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=6044273762&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-0778-02

DO - 10.1158/1078-0432.CCR-0778-02

M3 - Article

C2 - 15501957

AN - SCOPUS:6044273762

VL - 10

SP - 6807

EP - 6820

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 20

ER -